Cargando…

Improving TCR Gene Therapy for Treatment of Haematological Malignancies

Adoptive immunotherapy using TCR gene modified T cells may allow separation of beneficial Graft versus tumour responses from harmful GvHD. Improvements to this include methods to generate high avidity or high affinity TCR, improvements in vector design and reduction in mispairing. Following adoptive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicholson, Emma, Ghorashian, Sara, Stauss, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272793/ https://www.ncbi.nlm.nih.gov/pubmed/22319532 http://dx.doi.org/10.1155/2012/404081

Ejemplares similares

TCR Gene Therapy: Challenges, Opportunities, and Future Directions
por: Stauss, Hans J., et al.
Publicado: (2020)

Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo
por: Xue, Shao-An, et al.
Publicado: (2013)

Targeting hypoxia in solid and haematological malignancies
por: Harris, Bill, et al.
Publicado: (2022)

Modifications outside CDR1, 2 and 3 of the TCR variable β domain increase TCR expression and antigen-specific function
por: Degirmencay, Abdullah, et al.
Publicado: (2023)

Tuberculosis in Patients with Haematological Malignancies
por: Anibarro, Luis, et al.
Publicado: (2014)

Expression of testicular genes in haematological malignancies
por: Lim, S H, et al.
Publicado: (1999)

Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies
por: Lewis, Alexander C., et al.
Publicado: (2018)

Cancer stem cells in haematological malignancies
por: Zagozdzon, Radoslaw, et al.
Publicado: (2015)

The hypoxia signalling pathway in haematological malignancies
por: Irigoyen, Marta, et al.
Publicado: (2017)

The Application of CAR-T Cells in Haematological Malignancies
por: Skorka, Katarzyna, et al.
Publicado: (2020)

Clinical Proteomics of Biofluids in Haematological Malignancies
por: Dunphy, Katie, et al.
Publicado: (2021)

Chemical modification of melphalan as a key to improving treatment of haematological malignancies
por: Gajek, Arkadiusz, et al.
Publicado: (2020)

The Role of miRNA in Haematological Malignancy
por: Gounaris-Shannon, Stephanie, et al.
Publicado: (2013)

Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
por: Cai, Qing, et al.
Publicado: (2020)

Breast imaging findings in haematological malignancies
por: Glazebrook, K. N., et al.
Publicado: (2014)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Long Non-Coding RNAs in Haematological Malignancies
por: Garitano-Trojaola, Andoni, et al.
Publicado: (2013)

Components of the Lectin Pathway of Complement in Haematologic Malignancies
por: Cedzyński, Maciej, et al.
Publicado: (2020)

PARP Inhibitors and Haematological Malignancies—Friend or Foe?
por: Skelding, Kathryn A., et al.
Publicado: (2021)

Beta-D-Glucan in Patients with Haematological Malignancies
por: Mikulska, Malgorzata, et al.
Publicado: (2021)

Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies
por: Mynott, Rachel L., et al.
Publicado: (2023)

Targeting Metabolism and Autophagy in the Context of Haematologic Malignancies
por: Banerji, Versha, et al.
Publicado: (2012)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors
por: Lo Presti, Vania, et al.
Publicado: (2020)

Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma
por: Hotblack, Alastair, et al.
Publicado: (2018)

Survival of critically ill patients with haematological malignancies compared with patients without haematological malignancy
por: Pugh, R, et al.
Publicado: (2013)

PSYCHOLOGICAL ASPECTS OF HAEMATOLOGICAL MALIGNANCIES
por: Kulhara, P., et al.
Publicado: (1990)

Early integration of palliative care for patients with haematological malignancies
por: Shaulov, Adir, et al.
Publicado: (2022)

TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma
por: Strobel, Sophia B., et al.
Publicado: (2022)

CD8 T Cell Tolerance to a Tumor-Associated Self-Antigen Is Reversed by CD4 T Cells Engineered To Express the Same T Cell Receptor
por: Ghorashian, Sara, et al.
Publicado: (2015)

Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies
por: Parmesar, Kevon, et al.
Publicado: (2016)

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
por: Smith, A, et al.
Publicado: (2011)

Cancer Chemotherapy—Its role in the Treatment Strategy of Haematologic Malignancies and Solid Tumours
por: Crowther, D.
Publicado: (1977)

Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review
por: Pérez-Moreno, María Antonia, et al.
Publicado: (2023)

HAEMATOLOGY IN DIAGNOSIS AND TREATMENT
Publicado: (1969)

Crispr/Cas Mediated Deletion of PTPN22 in Jurkat T Cells Enhances TCR Signaling and Production of IL-2
por: Bray, Cara, et al.
Publicado: (2018)

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
por: Mehta, Palak H., et al.
Publicado: (2021)

Haematological malignancies implications during the times of the COVID-19 pandemic
por: Papakonstantinou, Eleni, et al.
Publicado: (2021)

Transient Receptor Potential (TRP) Channels in Haematological Malignancies: An Update
por: Maggi, Federica, et al.
Publicado: (2021)

Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”
por: Teppert, Karin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7058p3v27f8p06kqq3kam1t3q0